Scientific Research News

SAN MATEO, Calif.--(BUSINESS WIRE)--Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, received IDE approval from the FDA, enabling the company to commence a global, pivotal, randomized controlled trial, the FULFILL Study, in the United States and Australia. ULF Neuromodulation will be delivered via leads implanted in the epidural space, also known as Spinal Cord Stimulation (SCS). Presidio is...

BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics appoints Aleksandra Faust as Chief Artificial Intelligence Officer...

BOSTON--(BUSINESS WIRE)--The Termeer Foundation, a nonprofit organization dedicated to empowering leaders in life sciences, is proud to announce its new name: The Termeer Institute. This evolution reflects a significant milestone in the organization’s strategic commitment to developing life science leaders, building community across the life sciences ecosystem, and convening stakeholders to advance cures for rare diseases. “The Termeer Institute beautifully honors Henri’s legacy of leadership a...

ROCKVILLE, Md.--(BUSINESS WIRE)--The Maryland Tech Council, the largest technology and life sciences trade association in the state, is pleased to announce that Dr. Marty Makary, Commissioner of the Food and Drug Administration, will participate in a fireside chat at the 2025 Bio Innovation Conference on September 4, 2025 at the Bethesda North Marriott Hotel and Conference Center in Rockville, Maryland. Dr. Makary was confirmed on March 25, 2025 by a bipartisan vote of the U.S. Senate as the 27...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. “Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines throu...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in generating real-world evidence (RWE) from high-quality healthcare data today announced a partnership with Kythera Labs, a leading healthcare data and technology company, adding to the growing number of datasets and use cases for the Atropos Evidence™ Network including oncology. This is the first step in a multiyear agreement between the two companies committed to turning data and knowledge of molecular biology in health and disease...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare’s proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagno...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyze and...

BOSTON--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-respons...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced that the company will present intranasal human abusability data from cebranopadol, an investigational first-in-class oral dual NOP/MOP (dual-NMR) agonist, at the College on Problems of Drug Dependence (CPDD) Annual Meeting, taking place June 14-18, 2025, in New Orleans. The data will be presented in a late-breaking oral session and a poster presentation which highlig...